NTRA vs TMO
Natera, Inc. and Thermo Fisher Scientific, both Healthcare
Thermo Fisher Scientific is the larger company at $173B against $33B. Over the past year NTRA returned +140% against +42% for TMO. Ryufin's sector-relative Smart Score puts NTRA ahead, 10/10 against 9/10.
| Figure | NTRA | TMO |
|---|---|---|
| Last close | $339 | $634 |
| Market cap | $33B | $173B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 34.1 |
| Dividend yield | n/a | 0.3% |
| 1-year return | +140% | +42% |
| 5-year return | +201% | +19% |
| Ryufin Smart Scoresector-relative, 1–10 | 10/10 | 9/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Natera, Inc.
Revenue of $753M in Q2 2026, net income null. Its largest reported line is US, 98% of the disclosed total.
Thermo Fisher Scientific
Revenue of $12B in Q2 2026, net income $1.7B. Its largest reported line is Life Sciences Solutions, 38% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.